DCI para Sustancias Farmacéuticas

WHO Drug Information, Vol. 26, No.
3, 2012 Recommended INN: List 68
International Nonproprietary Names for

Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 68
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in Cumulative List
No. 14, 2011 (available in CD-ROM only).
Dénominations communes internationales

des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 68
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans
la Liste récapitulative No. 14, 2011 (disponible sur CD-ROM seulement).
Denominaciones Comunes Internacionales

para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 68
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran
reunidas en Cumulative List No. 14, 2011 (disponible sólo en CD-ROM).
301
Recommended INN: List 68 WHO Drug Information, Vol. 26, No. 3, 2012
Latin, English, French, Spanish:

Recommended INN Chemical name or description; Molecular formula; Graphic formula
DCI Recommandée Nom chimique ou description; Formule brute; Formule développée
DCI Recomendada Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada
acidum deoxycholicum
deoxycholic acid 3α,12α-dihydroxy-5β-cholan-24-oic acid
acide désoxycholique acide 3α,12α-dihydroxy-5β-cholan-24-oïque
ácido desoxicólico ácido 3α,12α-dihidroxi-5β-colan-24-oico
C24H40O4
H3C H
OH
H CH3 CO2H
H
CH3 H
H H
H
HO H
18
acidum florilglutamicum ( F)
18 18
florilglutamic acid ( F) (4S)-4-(3-[ F]fluoropropyl)-L-glutamic acid
18 18
acide florilglutamique ( F) acide (4S)-4-(3-[ F]fluoropropyl)-L-glutamique
18 18
ácido florilglútamico ( F) ácido (4S)-4-(3-[ F]fluoropropil)-L-glutámico
18
C8H14 FNO4
HO2C CO2H
H H NH2
[18F]
acidum tiazoticum
tiazotic acid [(5-methyl-1H-1,2,4-triazol-3-yl)sulfanyl]acetic acid
acide tiazotique acide [(5-méthyl-1H-1,2,4-triazol-3-yl)sulfanyl]acétique
ácido tiazótico ácido [(5-metil-1H-1,2,4-triazol-3-il)sulfanil]acético
C5H7N3O2S
HN N
CO2H
H3C N S
302
WHO Drug Information, Vol. 26, No. 3, 2012 Recommended INN: List 68
amitifadinum
amitifadine (1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
amitifadine (1R,5S)-1-(3,4-dichlorophényl)-3-azabicyclo[3.1.0]hexane
amitifadina (1R,5S)-1-(3,4-diclorofenil)-3-azabiciclo[3.1.0]hexano
C11H11Cl2N
H
N
Cl
Cl
bamosiranum
bamosiran siRNA inhibitor of β2-adrenergic receptor production;
RNA duplex of cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-
uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-
cytidylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-
uridylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-
cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-
thymidylyl-(3'→5')-thymidine with thymidylyl-(5'→3')-thymidylyl-
(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-adenylyl-
(5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-guanylyl-
(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-cytidylyl-(5'→3')-adenylyl-
(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-
(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidine
bamosiran petit ARN interférant (siRNA) inhibiteur de la production du récepteur

adrénergique β2;
duplex ARN du brin cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-
(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-
(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-
(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-uridylyl-
(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-
(3'→5')-thymidylyl-(3'→5')-thymidine avec le brin anti-sens
thymidylyl-(5'→3')-thymidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-
(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-
(5'→3')-cytidylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-adénylyl-
(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-
(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-
(5'→3')-cytidine
bamosirán ARN interferente pequeño (siRNA) inhibidor de la producción del

receptor adrenérgico β2
ARN dúplex de la cadena citidilil-(3'→5')-adenilil-(3'→5')-uridilil-
(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-
citidilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-guanilil-(3'→5')-uridilil-
(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-
citidilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-timidilil-(3'→5')-
timidina con la cadena antisentido timidilil-(5'→3')-timidilil-(5'→3')-
guanilil-(5'→3')-uridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-citidilil-
(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-
adenilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-citidilil-(5'→3')-uridilil-
(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-
(5'→3')-citidina
C401H500N150O290P40
(3'-5')CAUUGUGCAUGUGAUCCAG-dT-dT
(5'-3')dT-dT-GUAACACGUACACUAGGUC
303
brexpiprazolum
brexpiprazole 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-
2(1H)-one
brexpiprazole 7-{4-[4-(1-benzothiophén-4-yl)pipérazin-1-yl]butoxy}quinoléin-
2(1H)-one
brexpiprazol 7-{4-[4-(1-benzotiofen-4-il)piperazin-1-il]butoxi}quinolin-2(1H)-ona
C25H27N3O2S
H
O N O
N
S N
buparlisibum
buparlisib 5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-
2-amine
buparlisib 5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluorométhyl)pyridin-
2-amine
buparlisib 5-[2,6-bis(morfolin-4-il)pirimidin-4-il]-4-(trifluorometil)piridin-2-amina
C18H21F3N6O2
N N
N N
O
F3C NH2
camicinalum
camicinal 1-{4-[(3-fluorophenyl)amino]piperidin-1-yl}-2-(4-{[(3S)-3-
methylpiperazin-1-yl]methyl}phenyl)ethan-1-one
camicinal 1-{4-[(3-fluorophényl)amino]pipéridin-1-yl}-2-(4-{[(3S)-3-
méthylpipérazin-1-yl]méthyl}phényl)éthan-1-one
camicinal 1-{4-[(3-fluorofenil)amino]piperidin-1-il}-2-(4-{[(3S)-3-metilpiperazin-
1-il]metil}fenil)etan-1-ona
C25H33FN4O
N O F
HN
N
H CH3
N
H
304
caplacizumabum #
caplacizumab immunoglobulin VH-linker-VH fragment, anti-[Homo sapiens VWF
(von Willebrand factor) A1 domain], humanized monoclonal
antibody;
VH-linker-VH chain (1-259) [humanized VH (Homo sapiens IGHV3-
23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)] -
trialanyl linker (129-131) -[humanized VH (Homo sapiens IGHV3-
23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)
caplacizumab immunoglobuline fragment VH-linker-VH, anti-[Homo sapiens VWF

(facteur de von Willebrand) domaine A1], anticorps monoclonal
humanisé;
chaîne VH-linker-VH (1-259) [VH humanisé (Homo sapiens IGHV3-
23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-128)] -
trialanyl linker (129-131) -[VH humanisé (Homo sapiens IGHV3-
23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21] (132-259)
caplacizumab inmunoglobulina fragmento VH-conector-VH, anti-[VWF (factor de

von Willebrand) de Homo sapiens dominio A1], anticuerpo
monoclonal humanizado;
cadena VH-conector-VH (1-259) [VH humanizado (Homo sapiens
IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (123) [8.8.21] (1-
128)] -trialanil conector (129-131) -[VH humanizado (Homo sapiens
IGHV3-23*04 (82.50%) -(IGHD)-IGHJ4*01 L123>Q (254) [8.8.21]
(132-259)
EVQLVESGGG LVQPGGSLRL SCAASGRTFS YNPMGWFRQA PGKGRELVAA 50

ISRTGGSTYY PDSVEGRFTI SRDNAKRMVY LQMNSLRAED TAVYYCAAAG 100
VRAEDGRVRT LPSEYTFWGQ GTQVTVSSAA AEVQLVESGG GLVQPGGSLR 150
LSCAASGRTF SYNPMGWFRQ APGKGRELVA AISRTGGSTY YPDSVEGRFT 200
ISRDNAKRMV YLQMNSLRAE DTAVYYCAAA GVRAEDGRVR TLPSEYTFWG 250
QGTQVTVSS 259
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain 22-96 153-227
cerlapirdinum
cerlapirdine N,N-dimethyl-3-{[3-(naphthalene-1-sulfonyl)-1H-indazol-
5-yl]oxy}propan-1-amine
cerlapirdine N,N-diméthyl-3-{[3-(naphtaléne-1-sulfonyl)-1H-indazol-
5-yl]oxy}propan-1-amine
cerlapirdina N,N-dimetil-3-{[3-(naftaleno-1-sulfonil)-1H-indazol-5-il]oxi}propan-
1-amina
C22H23N3O3S
H
N
N
H3C
N O
CH3 S
O
O
dexmecamylaminum
dexmecamylamine (1R,2S,4S)-N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
dexmécamylamine (1R,2S,4S)-N,2,3,3-tétraméthylbicyclo[2.2.1]heptan-2-amine
dexmecamilamina (1R,2S,4S)-N,2,3,3-tetrametilbiciclo[2.2.1]heptan-2-amina
305
C11H21N
H
HN CH3
CH3
CH3
CH3
H
drisapersenum
drisapersen all-P-ambo-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-
thiocytidylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-
P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-
methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-
O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-
2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-
(3'→5')-2'-O-methyl-P-thioguanylyl-(3'→5')-2'-O-methyl-P-
thioguanylyl-(3'→5')-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-
P-thioadenylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-
methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-
methyl-P-thiocytidylyl-(3'→5')-2'-O-methyluridine
drisapersen tout-P-ambo-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-
thiocytidylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-
P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-O-
méthyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-
O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-
2'-O-méthyl-P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-
(3'→5')-2'-O-méthyl-P-thioguanylyl-(3'→5')-2'-O-méthyl-P-
thioguanylyl-(3'→5')-2'-O-méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyl-
P-thioadénylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-
méthyl-P-thiouridylyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-O-
méthyl-P-thiocytidylyl-(3'→5')-2'-O-méthyluridine
drisapersén todo-P-ambo-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil-
(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-
(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioguanilil-
(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tioadenilil-
(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tioadenilil-
(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-
2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-
metil-P-tioadenilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-
tiouridilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-O-metil-P-tiocitidilil-
(3'→5')-2'-O-metiluridina
C211H275N76O119P19S19
(3'-5')(P-thio)(Um-Cm-Am-Am-Gm-Gm-Am-Am-Gm-Am-Um-Gm-Gm-Cm-Am-Um-Um-Um-Cm-Um)
faldaprevirum
faldaprevir (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-methoxy-
2-[2-(2-methylpropanamido)-1,3-thiazol-4-yl]quinolin-4-yl}oxy]-
1-[(2S)-2-{[(cyclopentyloxy)carbonyl]amino}-
3,3-dimethylbutanoyl]pyrrolidine-2-carboxamido}-
2-ethenylcyclopropane-1-carboxylic acid
306
faldaprévir acide (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-méthoxy-

2-[2-(2-méthylpropanamido)-1,3-thiazol-4-yl]quinoléin-4-yl}oxy]-
1-[(2S)-2-{[(cyclopentyloxy)carbonyl]amino}-
3,3-diméthylbutanoyl]pyrrolidine-2-carboxamido}-
2-éthénylcyclopropane-1-carboxylique
faldaprevir ácido (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-methoxy-

2-[2-(2-metilpropanamido)-1,3-tiazol-4-il]quinolin-4-il}oxi]-
1-[(2S)-2-{[(ciclopentiloxi)carbonil]amino}-
3,3-dimetilbutanoil]pirrolidina-2-carboxamido}-2-etenilciclopropano-
1-carboxílico
C40H49BrN6O9S
S
Br
NH CH3
H3CO N
N
O CH3
CH3 H
H3 C
CH3 O
O
H
N H
O N N CO2H
H
O H
O CH2
H
flanvotumabum #
flanvotumab immunoglobulin G1-kappa, anti-[Homo sapiens TYRP1 (tyrosinase-
related protein 1, 5,6-dihydroxyindole-2-carboxylic acid oxidase,
DHICA oxidase, TRP1, melanoma antigen gp75)], Homo sapiens
monoclonal antibody;
gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV7-4-1*02
(95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)],
(222-215')-disulfide with kappa light chain (1'-215') [Homo sapiens
V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-108') -
IGKC*01 (109'-215')]; (228-228'':231-231'')-bisdisulfide dimer
flanvotumab immunoglobuline G1-kappa, anti-[Homo sapiens TYRP1 (protéine 1

apparentée à la tyrosinase, oxydase de l'acide 5,6-dihydroxyindole-
2-carboxylique, DHICA-oxydase, TRP1, antigène gp75 du
mélanome)], Homo sapiens anticorps monoclonal;
chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV7-4-1*02
(95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)],
(222-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo
sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ2*01) [6.3.10] (1'-
108') -IGKC*01 (109'-215')]; dimère (228-228'':231-231'')-bisdisulfure
flanvotumab inmunoglobulina G1-kappa, anti-[TYRP1 de Homo sapiens (proteina

1 relacionada con la tirosinasa), oxidasa del ácido 5,6-dihidroxiindol-
2-carboxílico, DHICA-oxidasa, TRP1, antígeno gp75 de melanoma)],
anticuerpo monoclonal de Homo sapiens;
cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV7-4-1*02
(95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03 (120-449)],
(222-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo
108') -IGKC*01 (109'-215')]; dímero (228-228'':231-231'')-bisdisulfuro
307
Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGSE LKKPGASVKI SCKASGYTFT SYAMNWVRQA PGQGLESMGW 50
INTNTGNPTY AQGFTGRFVF SMDTSVSTAY LQISSLKAED TAIYYCAPRY 100
SSSWYLDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449
Light chain / Chaîne légère / Cadena ligera

EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWLMYTFG 100
QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC 215
Intra-H 22-96 146-202 263-323 369-427
22''-96'' 146''-202'' 263''-323'' 369''-427''
Intra-L 23'-88' 135'-195'
23'''-88''' 135'''-195'''
Inter-H-L 222-215' 222''-215'''
Inter-H-H 228-228'' 231-231''
N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299''
follitropinum gamma #
follitropin gamma heterodimer of human glycoprotein hormones alpha chain and
follitropin subunit beta (FSH-beta), follicle stimulating hormone,
glycoform gamma
follitropine gamma hétérodimère constitué de la chaîne alpha des hormones

glycoprotéiques et de la sous-unité bêta de la follitropine (FSH-bêta)
humaines, hormone folliculostimulante, forme glycosylée gamma
folitropina gamma heterodímero formado por la cadena alfa de las hormonas

glicoprotéicas y la subunidad beta de la folitropina (FSH-beta)
humanas, hormona estimulante del folículo, forma glicosilada
gamma
C975H1493N267O305S26 (peptide)
Alpha subunit / Sous-unité alpha / Subunidad alfa

APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP LRSKKTMLVQ 50
KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACHCSTCYYH KS 92
Beta subunit / Sous-unité bêta / Subunidad beta

NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50'
CTFKELVYET VRVPGCAHHA DSLYTYPVAT QCHCGKCDSD STDCTVRGLG 100'
PSYCSFGEMK E 111'
7-31 10-60 28-82 32-84 59-87
3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'
Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-7' Asn-24' Asn-52 Asn-78
R66- R
-Man6-
R33--Gal4--Gl-N2- -Gl-NN
-Man--Gl-N
R44-
-Man3-
R33--Gal4--Gl-N2-
R = -Fuc or H, R3 = -Sia or H, R4 and R6 = R33--Gal4--Gl-N or H
308
gemcitabini elaidas
gemcitabine elaidate 2'-deoxy-2',2'-difluorocytidine 5'-(9E)-octadec-9-enoate
élaïdate de gemcitabine 5'-(9E)-octadéc-9-énoate de 2'-déoxy-2',2'-difluorocytidine
elaidato de gemcitabina 5'-(9E)-octadec-9-enoato de 2'-desoxi-2',2'-difluorocitidina
C27H43F2N3O5
NH2
O O N
O
O F
CH3
OH F
glyceroli phenylbutyras
glycerol phenylbutyrate propane-1,2,3-triyl tris(4-phenylbutanoate)
phénylbutyrate de glycérol tris(4-phénylbutanoate) de propane-1,2,3-triyle
fenilbutirato de glicerol tris(4-fenilbutanoato) de propano-1,2,3-triilo
C33H38O6
O
O O
O O
idursulfasum beta #
idursulfase beta iduronate 2-sulfatase (α-L-iduronate sulfate sulfatase), human pro-
enzyme produced in CHO cells (glycoform beta)
idursulfase bêta iduronate 2-sulfatase (α-L-iduronate sulfate sulfatase), proenzyme

humaine produite par des cellules CHO (glycoforme bêta)
idursulfasa beta iduronato 2-sulfatasa (α-L-iduronato sulfato sulfatasa), proenzima

humana producida por células CHO (forma glicosilada beta)
309
C2689H4051N699O793S13
SETQANSTTD ALNVLLIIVD DLRPSLGCYG DKLVRSPNID QLASHSLLFQ 50

NAFAQQAVCA PSRVSFLTGR RPDTTRLYDF NSYWRVHAGN FSTIPQYFKE 100
NGYVTMSVGK VFHPGISSNH TDDSPYSWSF PPYHPSSEKY ENTKTCRGPD 150
GELHANLLCP VDVLDVPEGT LPDKQSTEQA IQLLEKMKTS ASPFFLAVGY 200
HKPHIPFRYP KEFQKLYPLE NITLAPDPEV PDGLPPVAYN PWMDIRQRED 250
VQALNISVPY GPIPVDFQRK IRQSYFASVS YLDTQVGRLL SALDDLQLAN 300
STIIAFTSDH GWALGEHGEW AKYSNFDVAT HVPLIFYVPG RTASLPEAGE 350
KLFPYLDPFD SASQLMEPGR QSMDLVELVS LFPTLAGLAG LQVPPRCPVP 400
SFHVELCREG KNLLKHFRFR DLEEDPYLPG NPRELIAYSQ YPRPSDIPQW 450
NSDKPSLKDI KIMGYSIRTI DYRYTVWVGF NPDEFLANFS DIHAGELYFV 500
DSDPLQDHNM YNDSQGGDLF QLLMP 525
146-159 397-407
Modified residue / Résidu modifié / Residuo modificado

C H NH2
59 O
3-oxoAla CO2H
Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-6 Asn-90 Asn-119 Asn-221 Asn-255 Asn-300 Asn-488 Asn-512
inclacumabum #
inclacumab immunoglobulin G4-kappa, anti-[Homo sapiens SELP (selectin P,
CD62)], Homo sapiens monoclonal antibody;
gamma4 heavy chain (1-451) [Homo sapiens VH (IGHV3-13*01
(94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 hinge
S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfide with
kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01
(100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (230-
230'':233-233'')-bisdisulfide dimer
inclacumab immunoglobuline G4-kappa, anti-[Homo sapiens SELP (sélectine P,

CD62)], Homo sapiens anticorps monoclonal;
chaîne lourde gamma4 (1-451) [Homo sapiens VH (IGHV3-13*01
(94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 charnière
S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfure
avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA
(IGKV3-11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01
(108'-214')]; dimère (230-230'':233-233'')-bisdisulfure
inclacumab inmunoglobulina G4-kappa, anti-[SELP de Homo sapiens (selectina

P, CD62)], anticuerpo monoclonal de Homo sapiens ;
cadena pesada gamma4 (1-451) [Homo sapiens VH (IGHV3-13*01
(94.80%) -(IGHD)-IGHJ5*02) [8.7.18] (1-124) -IGHG4*01 bisagra
S10>P (232), CH2 L1.2>E (239) (125-451)], (138-214')-disulfuro con
la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-
11*01 (100.00%) -IGKJ4*02) [6.3.9] (1'-107') -IGKC*01 (108'-214')];
dímero (230-230'':233-233'')-bisdisulfuro
310

EVQLVESGGG LVRPGGSLRL SCAASGFTFS NYDMHWVRQA TGKGLEWVSA 50
ITAAGDIYYP GSVKGRFTIS RENAKNSLYL QMNSLRAGDT AVYYCARGRY 100
SGSGSYYNDW FDPWGQGTLV TVSSASTKGP SVFPLAPCSR STSESTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTKTYTCNVD HKPSNTKVDK RVESKYGPPC PPCPAPEFEG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN AKTKPREEQF 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI SKAKGQPREP 350
QVYTLPPSQE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSRLTVDKSR WQEGNVFSCS VMHEALHNHY TQKSLSLSLG 450
K 451

EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
Intra-H 22-95 151-207 265-325 371-429
22''-95'' 151''-207'' 265''-325'' 371''-429''
Intra-L 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 138-214' 138''-214'''
Inter-H-H 230-230'' 233-233''

301, 301''
lucerastatum
lucerastat (2R,3S,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
lucérastat (2R,3S,4R,5S)-1-butyl-2-(hydroxyméthyl)pipéridine-3,4,5-triol
lucerastat (2R,3S,4R,5S)-1-butil-2-(hidroximetil)piperidina-3,4,5-triol
C10H21NO4
OH
H
HO
H
N CH3
HO
H H
OH
naltalimidum
naltalimide 2-[17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-
6β-yl]isoindole-1,3-dione
naltalimide 2-[-17-(cyclopropylméthyl)-4,5α-époxy-3,14-dihydroxymorphinan-
6β-yl]-2H-isoindole-1,3-dione
naltalimida 2-[17-(ciclopropilmetil)-4,5α-epoxi-3,14-dihidroximorfinan-
6β-il]isoindol-1,3-diona
311
C28H28N2O5
H N
HO
O
O N
HO H H
netazepidum
netazepide 1-[(3R)-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-
2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-
3-[3-(methylamino)phenyl]urea
nétazépide 1-[(3R)-1-(3,3-diméthyl-2-oxobutyl)-2-oxo-5-(pyridin-2-yl)-
2,3-dihydro-1H-1,4-benzodiazépin-3-yl]-
3-[3-(méthylamino)phényl]urée
netazepida 1-[(3R)-1-(3,3-dimetil-2-oxobutil)-2-oxo-5-(piridin-2-il)-2,3-dihidro-
1H-1,4-benzodiazepin-3-il]-3-[3-(metilamino)fenil]urea
C28H30N6O3
CH3
H3C CH3
CH3
HN
O O
N O
H
N N
N H H
niraparibum
niraparib 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
niraparib 2-{4-[(3S)-pipéridin-3-yl]phényl}-2H-indazole-7-carboxamide
niraparib 2-{4-[(3S)-piperidin-3-il]fenil}-2H-indazol-7-carboxamida
C19H20N4O
H
N
N
H N
O NH2
312
ondelopranum
ondelopran 6-[2-fluoro-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyridine-
3-carboxamide
ondélopran 6-[2-fluoro-4-({[2-(oxan-4-yl)éthyl]amino}méthyl)phénoxy]pyridine-
3-carboxamide
ondeloprán 6-[2-fluoro-4-({[2-(oxan-4-il)etil]amino}metil)fenoxi]piridina-
3-carboxamida
C20H24FN3O3
O O
N N NH2
H
O
F
patiromerum calcium
patiromer calcium cross-linked polymer of calcium 2-fluoroprop-2-enoate with
diethenylbenzene and octa-1,7-diene
patiromère calcique polymère réticulé de 2-fluoroprop-2-énoate de calcium avec du

diéthénylbenzène et de l'octa-1,7-diène
patirómero cálcico polímero reticulado de 2-fluoroprop-2-enoato de calcio con

dietenilbenceno y octa-1,7-dieno
[[(C3H2FO2)2 Ca]9 [C8H14] [C10H10]]n
H2C CO2 CH2
F H2C
x y
x/2 Ca 2+ CH2
H2C
z
patritumabum #
patritumab immunoglobulin G1-kappa, anti-[Homo sapiens ERBB3 (receptor
tyrosine-protein kinase erbB-3, HER3)], Homo sapiens monoclonal
antibody;
(99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)],
V-KAPPA (IGKV4-1*01 (95.00%) -IGKJ1*01) [12.3.9] (1'-113') -
patritumab immunoglobuline G1-kappa, anti-[Homo sapiens ERBB3 (récepteur

tyrosine-protéine kinase erbB3, HER3)], Homo sapiens anticorps
monoclonal;
(99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)],
313
patritumab inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB3 (receptor de

tirosina-proteina kinasa erbB3, HER3)], anticuerpo monoclonal de
Homo sapiens;
(99.00%) -(IGHD)-IGHJ2*01) [8.7.11] (1-117) -IGHG1*03 (118-447)],

QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE 50
INHSGSTNYN PSLKSRVTIS VETSKNQFSL KLSSVTAADT AVYYCARDKW 100
TWYFDLWGRG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447

DIEMTQSPDS LAVSLGERAT INCRSSQSVL YSSSNRNYLA WYQQNPGQPP 50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYST 100
PRTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC 220
Intra-H 22-95 144-200 261-321 367-425
22''-95'' 144''-200'' 261''-321'' 367''-425''
Intra-L 23'-94' 140'-200'
23'''-94''' 140'''-200'''
Inter-H-L 220-220' 220''-220'''
Inter-H-H 226-226'' 229-229''

297, 297''
plazomicinum
plazomicin (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino-
6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2H-pyran-2-yl]oxy}-
2-{[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl]oxy}-
3-hydroxycyclohexyl]-2-hydroxybutanamide
plazomicine (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino-
6-{[(2-hydroxyéthyl)amino]méthyl}-3,4-dihydro-2H-pyran-2-yl]oxy}-
2-{[3-déoxy-4-C-méthyl-3-(méthylamino)-β-L-arabinopyranosyl]oxy}-
3-hydroxycyclohexyl]-2-hydroxybutanamide
plazomicina (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-{[(2S,3R)-3-amino-
6-{[(2-hidroxietil)amino]metil}-3,4-dihidro-2H-piran-2-il]oxi}-
2-{[3-desoxi-4-C-metil-3-(metilamino)-β-L-arabinopiranosil]oxi}-
3-hidroxiciclohexil]-2-hidroxibutanamida
C25H48N6O10
HO O
CH3 O
HO HN
NH2
H3C O HN
HN OH H OH
O HO
NH2
NH2 O
pradigastatum
pradigastat {(1r,4r)-4-[4-(5-{[6-(trifluoromethyl)pyridin-3-yl]amino}pyridin-2-yl)
phenyl]cyclohexyl}acetic acid
314
pradigastat acide {trans-4-[4-(5-{[6-(trifluorométhyl)pyridin-3-yl]amino}pyridin-

2-yl)phényl]cyclohexyl}acétique
pradigastat ácido {(1r,4r)-4-[4-(5-{[6-(trifluorometil)piridin-3-il]amino}piridin-2-il)

fenil]ciclohexil}acético
C25H24F3N3O2
CO2H
F 3C N N
N
H
pritelivirum
pritelivir N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-
2-yl)phenyl]acetamide
pritélivir N-méthyl-N-(4-méthyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-[4-(pyridin-
2-yl)phényl]acétamide
pritelivir N-metil-N-(4-metil-5-sulfamoil-1,3-tiazol-2-il)-2-[4-(pyridin-
2-il)fenil]acetamida
C18H18N4O3S2
N
CH3
O N NH2
S
N S O
O
CH3
quilizumabum #
quilizumab immunoglobulin G1-kappa, anti-[Homo sapiens IGHE connecting
region (CO) M1 prime (in alternatively spliced heavy chain of
membrane IgE on B cells)], humanized monoclonal antibody;
gamma1 heavy chain (1-447) [humanized VH (Homo sapiens
IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-
117) -Homo sapiens IGHG1*03 CH1 R120>K (214) (118-447)], (220-
219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA
(Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112')
-Homo sapiens IGKC*01 (113'-219')]; (226-226":229-229")-
bisdisulfide dimer
quilizumab immunoglobuline G1-kappa, anti-[Homo sapiens IGHE région de

connexion (CO) M1 prime (dans la chaîne lourde des IgE
membranaires à la surface des lymphocytes B, épissée de manière
alternative)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens
IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-
219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA
humanisé (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01)
[11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (226-
226":229-229")-bisdisulfure
315
quilizumab inmunoglobulina G1-kappa, anti-[Homo sapiens IGHE región de

conexión (CO) M1 prime (en la cadena pesada de las IgE de
membrana de la superficie de los linfocitos B, ensamblada de modo
alternativo)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens
IGHV3-48*01 (85.70%) -(IGHD)-IGHJ3*01 M123>L (112) [8.8.10] (1-
219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
humanizado (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01)
[11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (226-
226":229-229")-bisdisulfuro

EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYGIAWVRQA PGKGLEWVAF 50
ISDLAYTIYY ADTVTGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDN 100
WDAMDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250

DIQMTQSPSS LSASVGDRVT ITCRSSQSLV HNNANTYLHW YQQKPGKAPK 50
LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YYCSQNTLVP 100
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC 219
Intra-H 22-96 144-200 261-321 367-425
22''-96'' 144''-200'' 261''-321'' 367''-425''
Intra-L 23'-93' 139'-199'
23'''-93''' 139'''-199'''
Inter-H-L 220-219' 220''-219'''
Inter-H-H 226-226'' 229-229''

297, 297'' (non-fucosylated oligosaccharides)
radavirsenum
radavirsen all-P-ambo-P,2',3'-trideoxy-P-(dimethylamino)-5'-O-{P-[4-({2-[2-(2-
hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-N,N-
dimethylphosphonamidoyl}-(2'a→5')-P,2',3'-trideoxy-P-
(dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'-
trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-(2'a→5')-
P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-
(2'a→5')-P,3'-dideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'-
secothymidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-
2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-
imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-
2',3'-imino-2',3'-secoguanyly-(2'a→5')-P,2',3'-trideoxy-P-
(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-P,2',3'-
trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-
P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoguanyly-
(2'a→5')-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-
secoadenylyl-(2'a→5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino-
2',3'-secocytidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-
imino-2',3'-secothymidylyl-(2'a→5')-P,2',3'-trideoxy-P-
(dimethylamino)-2',3'-imino-2',3'-secocytidylyl-(2'a→5')-P,2',3'-
trideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secoadenylyl-(2'a→5')-
P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-2',3'-secothymidylyl-
(2'a→5')-P,2',3'-trideoxy-P-(piperazin-1-yl)-2',3'-imino-2',3'-
secocytidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-imino-
2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-2',3'-
imino-2',3'-secothymidylyl-(2'a→5')-P,3'-dideoxy-P-(dimethylamino)-
2',3'-imino-2',3'-secothymidine
316
radavirsen tout-P-ambo-P,2',3'-tridéoxy-P-(diméthylamino)-5'-O-{P-[4-({2-[2-(2-
hydroxyéthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-N,N-
diméthylphosphonamidoyl}-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-
P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl-
(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-
sécoguanylyl-(2'a→5')-P,3'-didéoxy-2',3'-imino-P-(pipérazin-1-yl)-
2',3'-sécothymidylyl-(2'a→5')-P,3'-didéoxy-P-(diméthylamino)-2',3'-
imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'-tridéoxy-P-
(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-
tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoguanylyl-(2'a→5')-
P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-
(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-
sécoadenylyl-(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-
2',3'-sécoguanylyl-(2'a→5')-P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-
imino-2',3'-sécoadénylyl-(2'a→5')-P,2',3'-tridéoxy-2',3'-imino-P-
(pipérazin-1-yl)-2',3'-sécocytidylyl-(2'a→5')-P,3'-didéoxy-P-
(diméthylamino)-2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-P,2',3'-
tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécocytidylyl-(2'a→5')-
P,2',3'-tridéoxy-P-(diméthylamino)-2',3'-imino-2',3'-sécoadénylyl-
(2'a→5')-P,3'-didéoxy-P-(dimethylamino)-2',3'-imino-2',3'-
sécothymidylyl-(2'a→5')-P,2',3'-tridéoxy-2',3'-imino-P-(pipérazin-1-
yl)-2',3'-sécocytidylyl-(2'a→5')-P,3'-didéoxy-P-(diméthylamino)-2',3'-
imino-2',3'-sécothymidylyl-(2'a→5')-P,3'-didéoxy-P-(diméthylamino)-
2',3'-imino-2',3'-sécothymidylyl-(2'a→5')-3'-déoxy-2',3'-imino-2',3'-
sécothymidine
radavirsén todo-P-ambo-P,2',3'-tridesoxi-P-(dimetilamino)-5'-O-{P-[4-({2-[2-(2-
hidroxietoxi)etoxi]etoxi}carbonil)piperazin-1-il]-N,N-
dimetilfosfonamidoil}-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-
imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-
2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-
(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')-P,3'-didesoxi-P-
(piperazin-1-il)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-didesoxi-P-
(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-
P-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,2',3'-
tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secoguanilil-(2'a→5')-
P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-
(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-2',3'-
secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-imino-
2',3'-secoguanilil-(2'a→5')-P,2',3'-tridesoxi-P-(dimetilamino)-2',3'-
imino-2',3'-secoadenilil-(2'a→5')-P,2',3'-tridesoxi-P-(piperazin-1-il)-
2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,3'-didesoxi-P-(dimetilamino)-
2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-tridesoxi-P-
(dimetilamino)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,2',3'-tridesoxi-
P-(dimetilamino)-2',3'-imino-2',3'-secoadenilil-(2'a→5')-P,3'-didesoxi-
P-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,2',3'-
tridesoxi-P-(piperazin-1-il)-2',3'-imino-2',3'-secocitidilil-(2'a→5')-P,3'-
didesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-
didesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secotimidilil-(2'a→5')-P,3'-
didesoxi-P-(dimetilamino)-2',3'-imino-2',3'-secotimidina
317
C253H398N116O87P20
O B(n) B(20)
O N O 1' O
2'a
HO N O N O NH
3 P P
5'
H 3C N O R(n) O 19
n = 1 - 19 CH3
B(1-20) : C-G-G-T-T-A-G-A-A-G-A-C-T-C-A-T-C-T-T-T
R(1-3) = R(5-11) = R(13-16) = R(18) = R(19) = -N(CH3)2
R(4) = R(12) = R(17) = HN N
rafigrelidum
rafigrelide 6,7-dichloro-3,3-dimethyl-5,10-dihydroimidazo[2,1-b]quinazolin-
2(3H)-one
rafigrélide 6,7-dichloro-3,3-diméthyl-1,5-dihydroimidazo[2,1-b]quinazolin-
2(3H)-one
rafigrelida 6,7-dicloro-3,3-dimetil-5,10-dihidroimidazo[2,1-b]quinazolin-
2(3H)-ona
C12H11Cl2N3O
H
N N
O
N
Cl
CH3
Cl H3C
refametinibum
refametinib N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-
1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
réfamétinib N-{3,4-difluoro-2-[(2-fluoro-4-iodophényl)amino]-6-méthoxyphényl}-
1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
refametinib N-{3,4-difluoro-2-[(2-fluoro-4-iodofenil)amino]-6-metoxifenil}-
1-[(2S)-2,3-dihidroxipropil]ciclopropano-1-sulfonamida
C19H20F3IN2O5S
CH3
F O
O O
S
F N OH
H
NH H OH
I F
318
rigosertibum
rigosertib N-[2-methoxy-5-({[(1E)-2-(2,4,6-
trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine
rigosertib N-[2-méthoxy-5-({[(1E)-2-(2,4,6-
triméthoxyphényl)éthényl]sulfonyl}méthyl)phényl]glycine
rigosertib N-[2-metoxi-5-({[(1E)-2-(2,4,6-
trimetoxifenil)etenil]sulfonil}metil)fenil]glicina
C21H25NO8S
H3CO OCH3
H
N CO2H
S
OCH3 O O
OCH3
riodipinum
riodipine dimethyl 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarboxylate
riodipine 4-[2-(difluorométhoxy)phényl]-2,6-diméthyl-1,4-dihydropyridine-
3,5-dicarboxylate de diméthyle
riodipino 4-[2-(difluorometoxi)fenil]-2,6-dimetil-1,4-dihidropiridina-
3,5-dicarboxilato de dimetilo
C18H19F2NO5
H
H3C N CH3
O O
H3C CH3
O O
O F
romosozumabum #
romosozumab immunoglobulin G2-kappa, anti-[Homo sapiens SOST (sclerostin)],
humanized monoclonal antibody;
gamma2 heavy chain (1-449) [humanized VH (Homo sapiens
IGHV1-2*02 (87.80%) -(IGHD)-IGHJ2*01 R120>Q (115), L123>T
(118) [8.8.16] (1-123) -Homo sapiens IGHG2*01 (124-449)], (137-
214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA
(Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9] (1'-107') -
Homo sapiens IGKC*01 (108'-214')]; (225-225":226-226":229-
229":232-232")-tetrakisdisulfide dimer
romosozumab immunoglobuline G2-kappa, anti-[Homo sapiens SOST

(sclérostine)], anticorps monoclonal humanisé;
chaîne lourde gamma2 (1-449) [VH humanisé (Homo sapiens
214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA
humanisé (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02) [6.3.9]
(1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (225-
225":226-226":229-229":232-232")-tétrakisdisulfure
319
romosozumab inmunoglobulina G2-kappa, anti-[SOST (esclerostina) de Homo

sapiens], anticuerpo monoclonal humanizado;
cadena pesada gamma2 (1-449) [VH humanizado (Homo sapiens
214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA
humanizado (Homo sapiens IGKV1-33*01 (89.50%) -IGKJ4*02)
[6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (225-
225":226-226":229-229":232-232")-tetrakisdisulfuro

EVQLVQSGAE VKKPGASVKV SCKASGYTFT DYNMHWVRQA PGQGLEWMGE 50
INPNSGGAGY NQKFKGRVTM TTDTSTSTAY MELRSLRSDD TAVYYCARLG 100
YDDIYDDWYF DVWGQGTTVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSNFG 200
TQTYTCNVDH KPSNTKVDKT VERKCCVECP PCPAPPVAGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TFRVVSVLTV VHQDWLNGKE YKCKVSNKGL PAPIEKTISK TKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPML 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449

DIQMTQSPSS LSASVGDRVT ITCRASQDIS NYLNWYQQKP GKAPKLLIYY 50
TSRLLSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GDTLPYTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
LSSPVTKSFN RGEC 214
Intra-H 22-96 150-206 263-323 369-427
22''-96'' 150''-206'' 263''-323'' 369''-427''
Intra-L 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 137-214' 137''-214'''
Inter-H-H 225-225'' 226-226'' 229-229'' 232-232''

299, 299''
samidorphanum
samidorphan 17-(cyclopropylmethyl)-4,14-dihydroxy-6-oxomorphinan-
3-carboxamide
samidorphan 17-(cyclopropylméthyl)-4,14-dihydroxy-6-oxomorphinane-
3-carboxamide
samidorfano 17-(ciclopropilmetil)-4,14-dihidroxi-6-oxomorfinan-3-carboxamida
C21H26N2O4
H N
HO
H2N OH O
O
sapitinibum
sapitinib 2-[4-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-
6-yl}oxy)piperidin-1-yl]-N-methylacetamide
sapitinib 2-[4-({4-[(3-chloro-2-fluorophényl)amino]-7-méthoxyquinazolin-
6-yl}oxy)pipéridin-1-yl]-N-méthylacétamide
320
sapitinib 2-[4-({4-[(3-cloro-2-fluorofenil)amino]-7-metoxiquinazolin-
6-il}oxi)piperidin-1-il]-N-metilacetamida
C23H25ClFN5O3
CH3
H
N O N
H3 C N
O N
O F
HN Cl
sarilumabum #
sarilumab immunoglobulin G1-kappa, anti-[Homo sapiens IL6R (interleukin 6
receptor, IL-6R, CD126)], Homo sapiens monoclonal antibody;
(94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)],
V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ2*01) [6.3.9] (1'-107') -
sarilumab immunoglobuline G1-kappa, anti-[Homo sapiens IL6R (récepteur de

l'interleukine 6, IL-6R, CD126)], Homo sapiens anticorps
monoclonal;
(94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)],
sarilumab inmunoglobulina G1-kappa, anti-[Homo sapiens IL6R (receptor de la

interleukina 6, IL-6R, CD126)], anticuerpo monoclonal de Homo
sapiens;
(94.90%) -(IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*01 (117-446)],

EVQLVESGGG LVQPGRSLRL SCAASRFTFD DYAMHWVRQA PGKGLEWVSG 50
ISWNSGRIGY ADSVKGRFTI SRDNAENSLF LQMNGLRAED TALYYCAKGR 100
DSFDIWGQGT MVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446

DIQMTQSPSS VSASVGDRVT ITCRASQGIS SWLAWYQQKP GKAPKLLIYG 50
ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFASYYCQQ ANSFPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
LSSPVTKSFN RGEC 214
Intra-H 22-96 143-199 260-320 366-424
22''-96'' 143''-199'' 260''-320'' 366''-424''
Intra-L 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 219-214' 219''-214'''
Inter-H-H 225-225'' 228-228''

296, 296''
321
secretinum humanum
secretin human human peptide hormone secretin;
L-histidyl-L-seryl-L-aspartylglycyl-L-threonyl-L-phenylalanyl-
L-threonyl-L-seryl-L-glutamyl-L-leucyl-L-seryl-L-arginyl-L-leucyl-
L-arginyl-L-glutamylglycyl-L-alanyl-Larginyl-L-leucyl-L-glutaminyl-
L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide
sécrétine humaine sécrétine humaine hormone peptidique;

L-histidyl-L-séryl-L-aspartylglycyl-L-thréonyl-L-phénylalanyl-
L-thréonyl-L-séryl-L-glutamyl-L-leucyl-L-séryl-L-arginyl-L-leucyl-
L-arginyl-L-glutamylglycyl-L-alanyl-L-arginyl-L-leucyl-L-glutaminyl-
L-arginyl-L-leucyl-L-leucyl-L-glutaminylglycyl-L-leucyl-L-valinamide
secretina humana secretina humana, hormona peptídica;

L-histidil-L-seril-L-aspartilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-
L-glutamil-L-leucil-L-seril-L-arginil-L-leucil-L-arginil-L-glutamilglicil-
L-alanil-L-arginil-L-leucil-L-glutaminil-L-arginil-L-leucil-L-leucil-
L-glutaminilglicil-L-leucil-L-valinamida
C130 H220 N44 O40
HSDGTFTSEL SRLREGARLQ RLLQGLV 27
Modified residue / Résidu modifié / Residuo modificado

H NH2
V H3C NH2
27
valinamide
CH3 O
selisistatum
selisistat rac-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
sélisistat rac-6-chloro-2,3,4,9-tétrahydro-1H-carbazole-1-carboxamide
selisistat rac-6-cloro-2,3,4,9-tetrahidro-1H-carbazol-1-carboxamida
C13H13ClN2O
H O
N H
and enantiomer
NH2 et énantiomère
y enantiómero
Cl
setrobuvirum
setrobuvir N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-
1,2,4a,5,6,7,8,8a-octahydro-5,8-methanoquinolin-3-yl}-1,1-dioxo-
6
1,4-dihydro-1λ ,2,4-benzothiadiazin-7-yl)methanesulfonamide
sétrobuvir N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorophényl)méthyl]-4-hydroxy-2-oxo-
1,2,4a,5,6,7,8,8a-octahydro-5,8-méthanoquinoléin-3-yl}-1,1-dioxo-
6
1,4-dihydro-1λ ,2,4-benzothiadiazin-7-yl)méthanesulfonamide
setrobuvir N-(3-{(4aR,5S,8R,8aS)-1-[(4-fluorofenil)metil]-4-hidroxi-2-oxo-
1,2,4a,5,6,7,8,8a-octahidro-5,8-metanoquinolin-3-il}-1,1-dioxo-
6
1,4-dihidro-1λ ,2,4-benzotiadiazin-7-il)metanosulfonamida
322
C25H25FN4O6S2
F
H
H
N O
H
N
O O
H
H OH N S
S N CH3
H
O O
sevuparinum natricum
sevuparin sodium sodium salt of a low molecular mass heparin obtained by
depolymerization through periodate oxidation of heparin from porcine
intestinal mucosa, followed by reduction and mild acid hydrolysis of
the product; the majority of the components have a 2-amino-
2-deoxy-D-glucopyranose derivative structure at both ends of their
chain, the one at the reducing end can be substituted with threonic
acid or erythronic acid; the relative average molecular mass range is
approximately 7,500 daltons with about 90% ranging between 2,000
and 15,000 daltons; the degree of sulfation is 2 to 2.5 per
disaccharidic unit
sévuparine sodique sel sodique d'une héparine de basse masse moléculaire obtenue par
dépolymérisation, au moyen d'une oxydation periodique, d'héparine
de muqueuse intestinale de porc, suivi par une réduction et par une
hydrolyse douce; la majorité des composants de la sévuparine
sodique possèdent une structure 2-amino-2-déoxy-D-glucopyranose
aux deux extrémités, la réductrice peut être substituée par un acide
thréonique ou érythronique; la masse moléculaire relative moyenne
est approximativement de 7500 daltons, et celles de 90% sont
comprises entre 2000 à 15000; le degré de sulfatation est de 2 à 2,5
par unité disaccharide.
sevuparina sódica sal sódica de una heparina de baja masa molecular obtenida por
despolimerización, mediante oxidación periodica, de heparina de
mucosa intestinal porcina, seguida de reducción e hidrólisis con
ácido débil; la mayoría de los componentes de la sevuparina sódica
tienen una estructura 2-amino-2-desoxi-D-glucopiranosa en los dos
extremos, el reductor puede estar substituido con un ácido treónico
o eritrónico; la masa molecular relativa media es aproximadamente
de 7500 dalton, y con el 90% comprendido entre 2000 y 15000; el
grado de sulfatación es de 2 a 2,5 por unidad de disacárido
solitomabum #
solitomab immunoglobulin scFv-scFv, anti-[Homo sapiens EPCAM (epithelial
cell adhesion molecule, tumor-associated calcium signal transducer
1, TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2,
epithelial glycoprotein 2, EGP-2, KSA, KS1/4 antigen, M4S1, tumor
antigen 17-1A, Ep-CAM, EpCAM, CD326)]/anti-[Homo sapiens
CD3E (CD3 epsilon)], Mus musculus monoclonal antibody bispecific
single chain;
scFv anti-EPCAM [Mus musculus V-KAPPA (IGKV8-19*01
(98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer
tris(tetraglycyl-seryl) linker (114-128) -Mus musculus VH (IGHV1-
54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-
248)] -5-mer tetraglycyl-seryl linker (249-253) -scFv anti-CD3E
[humanized VH (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)-
IGHJ6*01) [8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA
(Mus musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493)
[5.3.9] (391-496)] -hexahistidine (497-502)
323
solitomab immunoglobuline scFv-scFv, anti-[Homo sapiens EPCAM (molécule

d'adhésion des cellules épithéliales, transducteur 1 du signal calcium
associé aux tumeurs, TACSTD1, protéine 2 associée aux tumeurs
gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2,
KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, Ep-CAM,
EpCAM, CD326)]/anti-[Homo sapiens CD3E (CD3 epsilon)], Mus
musculus anticorps monoclonal bispécifique à chaîne unique;
(98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer
tris(tétraglycyl-séryl) linker (114-128) -Mus musculus VH (IGHV1-
54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-
248)] -5-mer tétraglycyl-séryl linker (249-253) -scFv anti-CD3E [VH
humanisé (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)-IGHJ6*01)
[8.8.12] (254-372) -18-mer linker (373-390) -V-KAPPA (Mus
musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493) [5.3.9]
(391-496)] -hexahistidine (497-502)
solitomab inmunoglobulina scFv-scFv, anti-[EPCAM de Homo sapiens

(molécula de adhesión de células epiteliales, transductor 1 de la
señal de calcio asociado a tumores, TACSTD1, proteina 2 asociada
a tumores gastrointestinales, GA733-2, glicoproteina epitelial 2,
EGP-2, KSA, antígeno KS1/4, M4S1, antígeno tumoral 17-1A, Ep-
CAM, EpCAM, CD326)]/anti-[Homo sapiens CD3E (CD3 epsilon)],
anticuerpo monoclonal biespecifico monocatenario de Mus
musculus;
(98.00%)-IGKJ5*01 L126>I (112)) [12.3.9] (1-113) -15-mer
tris(tetraglicil-seril) conector (114-128) -Mus musculus VH (IGHV1-
54*01 (85.90%)-(IGHD)-IGHJ4*01, S123>T (243)) [8.8.14] (129-
248)] -5-mer tetraglicil-seril conector (249-253) -scFv anti-CD3E [VH
humanizado (Homo sapiens IGHV1-46*01 (82.50%)-(IGHD)-
IGHJ6*01) [8.8.12] (254-372) -18-mer conector (373-390) -V-KAPPA
(Mus musculus IGKV4-59*01 (81.70%)-IGKJ1*01 L124>V (493)
[5.3.9] (391-496)] -hexahistidina (497-502)
ELVMTQSPSS LTVTAGEKVT MSCKSSQSLL NSGNQKNYLT WYQQKPGQPP 50

KLLIYWASTR ESGVPDRFTG SGSGTDFTLT ISSVQAEDLA VYYCQNDYSY 100
PLTFGAGTKL EIKGGGGSGG GGSGGGGSEV QLLEQSGAEL VRPGTSVKIS 150
CKASGYAFTN YWLGWVKQRP GHGLEWIGDI FPGSGNIHYN EKFKGKATLT 200
ADKSSSTAYM QLSSLTFEDS AVYFCARLRN WDEPMDYWGQ GTTVTVSSGG 250
GGSDVQLVQS GAEVKKPGAS VKVSCKASGY TFTRYTMHWV RQAPGQGLEW 300
IGYINPSRGY TNYADSVKGR FTITTDKSTS TAYMELSSLR SEDTATYYCA 350
RYYDDHYCLD YWGQGTTVTV SSGEGTSTGS GGSGGSGGAD DIVLTQSPAT 400
LSLSPGERAT LSCRASQSVS YMNWYQQKPG KAPKRWIYDT SKVASGVPAR 450
FSGSGSGTDY SLTINSLEAE DAATYYCQQW SSNPLTFGGG TKVEIKHHHH 500
HH 502
Intra-chain 23-94 151-225 275-349 413-477

305 (but Pro in 306)
sovaprevirum
sovaprevir (2S,4R)-1-[(2S)-2-tert-butyl-4-oxo-4-(piperidin-1-yl)butanoyl]-
N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-
2-ethenylcyclopropyl}-4-[(7-methoxy-2-phenylquinolin-
4-yl)oxy]pyrrolidine-2-carboxamide
324
sovaprévir (2S,4R)-1-[(2S)-2-tert-butyl-4-oxo-4-(pipéridin-1-yl)butanoyl]-
N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-
2-éthénylcyclopropyl}-4-[(7-méthoxy-2-phénylquinoléin-
4-yl)oxy]pyrrolidine-2-carboxamide
sovaprevir (2S,4R)-1-[(2S)-2-terc-butil-4-oxo-4-(piperidin-1-il)butanoil]-
N-{(1R,2S)-1-[(ciclopropanosulfonil)carbamoil]-2-etenilciclopropil}-
4-[(7-metoxi-2-fenilquinolin-4-il)oxi]pirrolidina-2-carboxamida
C43H53N5O8S
H3CO N
CH3 H
H 3C
CH3 O
O
H O O O
N H
N N S
N
O H H
O
H
CH2
sutezolidum
sutezolid N-({(5S)-3-[3-fluoro-4-(thiomorpholin-4-yl)phenyl]-2-oxo-
1,3-oxazolan-5-yl}methyl)acetamide
sutézolid N-({(5S)-3-[3-fluoro-4-(thiomorpholin-4-yl)phényl]-2-oxo-
1,3-oxazolidin-5-yl}méthyl)acétamide
sutezolid N-({(5S)-3-[3-fluoro-4-(tiomorfolin-4-il)fenil]-2-oxo-1,3-oxazolan-
5-il}metil)acetamida
C16H20FN3O3S
O O
H H
H 3C N
N F
O
N
S
tanzisertibum
tanzisertib (1r,4r)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophenyl)amino]-
9H-purin-2-yl}amino)cyclohexan-1-ol
tanzisertib (1r,4r)-4-({9-[(3S)-oxolan-3-yl]-8-[(2,4,6-trifluorophényl)amino]-
9H-purin-2-yl}amino)cyclohexan-1-ol
tanzisertib (1r,4r)-4-({9-[(3S)-oxolan-3-il]-8-[(2,4,6-trifluorfenil)amino]-9H-purin-
2-il}amino)ciclohexan-1-ol
325
C21H23F3N6O2
F
F
H
N
HO N
NH F
N N N
H H H
tavaborolum
tavaborole 5-fluoro-2,1-benzoxaborol-1(3H)-ol
tavaborole 5-fluoro-2,1-benzoxaborol-1(3H)-ol
tavaborol 5-fluoro-2,1-benzoxaborol-1(3H)-ol
C7H6BFO2
OH
B
O
F
tedatioxetinum
tedatioxetine 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
tédatioxétine 4-{2-[(4-méthylphényl)sulfanyl]phényl}pipéridine
tedatioxetina 4-{2-[(4-metilfenil)sulfanil]fenil}piperidina
C18H21NS
S NH
H3C
tipiracilum
tipiracil 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-
2,4-(1H,3H)-dione
tipiracil 5-chloro-6-[(2-iminopyrrolidin-1-yl)méthyl]pyrimidine-
2,4-(1H,3H)-dione
tipiracilo 5-cloro-6-[(2-iminopirrolidin-1-il)metil]pirimidina-2,4-(1H,3H)-diona
C9H11ClN4O2
O
HN NH
N
O
HN Cl
326
tirasemtivum
tirasemtiv 6-ethynyl-1-(pentan-3-yl)-2H-imidazo[4,5-b]pyrazin-2-one
tirasemtiv 6-éthynyl-1-(pentan-3-yl)-1,3-dihydro-2H-imidazo[4,5-b]pyrazin-
2-one
tirasemtiv 6-etinil-1-(pentan-3-il)-2H-imidazo[4,5-b]pirazin-2-ona
C12H14N4O
H3C
HC CH3
N N
O
N N
H
tozadenantum
tozadenant 4-hydroxy-N-[4-methoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]-
4-methylpiperidine-1-carboxamide
tozadénant 4-hydroxy-N-[4-méthoxy-7-(morpholin-4-yl)-1,3-benzothiazol-2-yl]-
4-méthylpipéridine-1-carboxamide
tozadenant 4-hidroxi-N-[4-metoxi-7-(morfolin-4-il)-1,3-benzotiazol-2-il]-
4-metilpiperidina-1-carboxamida
C19H26N4O4S
N O
CH3
S N
OH
NH
N
OCH3
trebananibum #
trebananib immunoglobulin G1 Fc fragment fused with two synthetic
polypeptides that bind the Homo sapiens ANGPT2 (angiopoietin 2);
methionyl (1) -gamma1 heavy chain fragment (2-228) [Homo
sapiens IGHG1*01 hinge (EPKSC 1-5>del) (2-11), CH2 (12-121),
CH3 (122-228)] fused, at the C-terminal end, with a synthetic
polypeptide that comprises two 14-mer amino acid repeats that bind
angiopoietin 2 (229-287) [linker (229-235) -14-mer (236-249) -linker
(250-271) -14-mer (272-285) -leucyl-glutamate]; (7-7':10-10')-
bisdisulfide dimer
trébananib immunoglobuline G1 fragment Fc fusionné à deux polypeptides

synthétiques qui se lient à l'Homo sapiens ANGPT2 (angiopoïétine
2);
méthionyl (1) -fragment de chaîne gamma1 (2-228) [Homo sapiens
IGHG1*01 charnière (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3
(122-228)] fusionné, à l'extrémité C-terminale, à un polypeptide
synthétique qui comprend deux motifs répétés de 14 acides aminés
qui se lient à l'angiopoïétine 2 (229-287) [linker (229-235) -14-mer
(236-249) -linker (250-271) -14-mer (272-285) -leucyl-glutamate];
dimère (7-7':10-10')-bisdisulfure
327
trebananib inmunoglobulina G1 fragmento Fc fusionado con dos polipéptidos

sintéticos que se unen a la ANGPT2 (angiopoyetina 2) de Homo
sapiens;
metionil (1) -fragmento de cadena gamma1 (2-228) [Homo sapiens
IGHG1*01 bisagra (EPKSC 1-5>del) (2-11), CH2 (12-121), CH3
(122-228)] fusionada con el extremo C-terminal de un polipéptido
sintético que comprende dos secuencias repetidas de 14
aminoácidos que se unen a la angiopoyetina 2 (229-287) [conector
(229-235) -14-mer (236-249) -conector (250-271) -14-mer (272-285)
-leucil-glutamato]; dímero (7-7':10-10')-bisdisulfuro
MDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHE 50

DPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEY 100
KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLV 150
KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ 200
GNVFSCSVMH EALHNHYTQK SLSLSPGKGG GGGAQQEECE WDPWTCEHMG 250
SGSATGGSGS TASSGSGSAT HQEECEWDPW TCEHMLE 287
Intra-chain 42-102 148-206 239-246 275-282
42'-102' 148'-206' 239'-246' 275'-282'
Inter-chains 7-7' 10-10'

78, 78'
trelagliptinum
trelagliptin 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-
3,4-dihydropyrimidin-1(2H)-yl}methyl)-4-fluorobenzonitrile
trélagliptine 2-({6-[(3R)-3-aminopipéridin-1-yl]-3-méthyl-2,4-dioxo-
3,4-dihydropyrimidin-1(2H)-yl}méthyl)-4-fluorobenzonitrile
trelagliptina 2-({6-[(3R)-3-aminopiperidin-1-il]-3-metil-2,4-dioxo-
3,4-dihidropirimidin-1(2H)-il}metil)-4-fluorobenzonitrilo
C18H20FN5O2
H
H2N
N CN
O N O
CH3 F
umeclidinii bromidum
umeclidinium bromide 1-{2-[(benzyl)oxy]ethyl}4-[hydroxydi(phenyl)methyl]-
1-azabicyclo[2.2.2]octan-1-ium bromide
bromure d’uméclidinium bromure de 1-{2-[(benzyl)oxy]éthyl}-4-[hydroxydi(phényl)méthyl]-

1-azabicyclo[2.2.2]octanium
bromuro de umeclidinio bromuro de 1-{2-[(bencil)oxi]etil}4-[hidroxidi(fenil)metil]-

1-azabiciclo[2.2.2]octan-1-io
328
C29H34BrNO2
N Br
O
OH
vapendavirum
vapendavir 3-ethoxy-6-{2-[1-(6-methylpyridazin-3-yl)piperidin-4-yl]ethoxy}-
1,2-benzoxazole
vapendavir 3-éthoxy-6-{2-[1-(6-méthylpyridazin-3-yl)pipéridin-4-yl]éthoxy}-
1,2-benzoxazole
vapendavir 3-etoxi-6-{2-[1-(6-metilpiridazin-3-il)piperidin-4-il]etoxi}-
1,2-benzoxazol
C21H26N4O3
H 3C N
N O N
CH3
O
N
vonoprazanum
vonoprazan 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]-
N-methylmethanamine
vonoprazan 1-[5-(2-fluorophényl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]-
N-méthylméthanamine
vonoprazán 1-[5-(2-fluorofenil)-1-(piridina-3-sulfonil)-1H-pirrol-3-il]-
N-metilmetanamina
C17H16FN3O2S
O
N
O S
N
CH3
F NH
vortioxetinum
vortioxetine 1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine
vortioxétine 1-{2-[(2,4-diméthylphényl)sulfanyl]phényl}pipérazine
vortioxetina 1-{2-[(2,4-dimetilfenil)sulfanil]fenil}piperazina
329
C18H22N2S
N
S NH
H3C CH3
330
AMENDMENTS TO PREVIOUS LISTS

MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES
Recommended International Non Proprietary Names (Rec. INN): List 17

(Chronicle of the WHO, 1977, Vol. 31, No. 10)
p. 7 oxitropii bromidum
oxitropium bromide replace the description and the structure by the following ones
(1R,2R,4S,5S,7s,9s)-9-ethyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-
2,4
9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0 ]nonane bromide
H
H
O
H CH3
N O Br
O
H CH3
H H
OH
Dénominations communes internationales recommandées (DCI Rec.): Liste 17

(Chronique de l'OMS, Vol. 31, No. 10, 1977)
bromure d’oxitropium remplacer la description et la structure par les suivantes
bromure de (1R,2R,4S,5S,7s,9s)-9-éthyl-7-{[(2S)-3-hydroxy-
2,4
2-phénylpropanoyl]oxy}-9-méthyl-3-oxa-9-azoniatricyclo[3.3.1.0 ]nonane
H
H
O
H CH3
N O Br
O
H CH3
H H
OH
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 17

(Crónica de la OMS, Vol. 31, No. 10, 1977)
bromuro de oxitropio sustitúyase la descripción y la estructura por las siguientes
bromuro de (1R,2R,4S,5S,7s,9s)-9-etil-7-{[(2S)-2-fenil-3-hidroxipropanoil]oxi}-
2,4
9-metil-3-oxa-9-azoniatriciclo[3.3.1.0 ]nonano
H
H
O
H CH3
N O Br
O
H CH3
H H
OH
331

(WHO Drug Information, Vol. 21, No. 3, 2007)
p. 260 ulipristalum
& 261 ulipristal replace the structure by the following
ulipristal remplacer la structure par la suivante
ulipristal sustitúyase la estructura por la siguiente
CH3
N O
H3C CH3
H CH3
OH
H
H
O

p. 229 conestatum alfa #

conestat alfa replace the structure by the following
conestat alfa remplacer la structure par la suivante
conestat alfa sustitúyase la estructura por la siguiente
NPNATSSSSQ DPESLQDRGE GKVATTVISK MLFVEPILEV SSLPTTNSTT 50

NSATKITANT TDEPTTQPTT EPTTQPTIQP TQPTTQLPTD SPTQPTTGSF 100
CPGPVTLCSD LESHSTEAVL GDALVDFSLK LYHAFSAMKK VETNMAFSPF 150
SIASLLTQVL LGAGENTKTN LESILSYPKD FTCVHQALKG FTTKGVTSVS 200
QIFHSPDLAI RDTFVNASRT LYSSSPRVLS NNSDANLELI NTWVAKNTNN 250
KISRLLDSLP SDTRLVLLNA IYLSAKWKTT FDPKKTRMEP FHFKNSVIKV 300
PMMNSKKYPV AHFIDQTLKA KVGQLQLSHN LSLVILVPQN LKHRLEDMEQ 350
ALSPSVFKAI MEKLEMSKFQ PTLLTLPRIK VTTSQDMLSI MEKLEFFDFS 400
YDLNLCGLTE DPDLQVSAMQ HQTVLELTET GVEAAAASAI SVARTLLVFE 450
VQQPFLFVLW DQQHKFPVFM GRVYDPRA 478
101-406 108-183
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

Asn-3 Thr-26 Ser-42 Asn-47 Thr-49 Asn-59 Thr-61
Thr-66 Thr-70 Thr-74 Asn-216 Asn-231 Asn-330
Recommanded International Non Proprietary Names (Rec. INN): List 61

Denominations communes internationales recommandées (DCI Rec.): Liste 61
p. 67 macitentanum
macitentan replace the chemical name by the following
N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}
pyrimidin-4-yl]-N'-propylsulfuric diamide
332
Recommanded International Non Proprietary Names (Rec. INN): List 62

Denominations communes internationales recommandées (DCI Rec.): Liste 62
p. 263 & solanezumabum #

264
solanezumab replace the description and the structure by the following ones
solanezumab remplacer la description et la structure par les suivantes
solanezumab sustitúyase la descripción y la estructura por las siguientes
immunoglobulin G1-kappa, anti-[Homo sapiens amyloid-beta (Abeta) peptide soluble

monomer], humanized monoclonal antibody;
gamma1 heavy chain [humanized VH (Homo sapiens IGHV3-23*04 (87.60%) -
(IGHD)-IGHJ4*01) [8.8.5] (1-112) -Homo sapiens IGHG1*01 (113-442)], (215-219')-
disulfide with kappa light chain (1’-219’) [humanized V-KAPPA (Homo sapiens
IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-
219')]; (221-221":224-224")-bisdisulfide dimer
immunoglobuline G1-kappa, anti-[Homo sapiens amyloïde-bêta (Abeta) peptide

monomère soluble], anticorps monoclonal humanisé;
chaîne lourde gamma1 [VH humanisé (Homo sapiens IGHV3-23*04 (87.60%) -
disulfure avec la chaîne légère kappa (1’-219’) [V-KAPPA humanisé (Homo sapiens
IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-
219')]; dimère (221-221":224-224")-bisdisulfure
inmunoglobulina G1-kappa, anti-[péptido amiloide-beta (Abeta) monomèrico soluble

de Homo sapiens], anticuerpo monoclonal humanizado;
cadena pesada gamma1 [VH humanizado (Homo sapiens IGHV3-23*04 (87.60%) -
disulfuro con la cadena ligera kappa (1’-219’) [V-KAPPA humanizado (Homo
sapiens IGKV2-30*01 (90.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens
IGKC*01 (113'-219')]; dímero (221-221":224-224")-bisdisulfuro

EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYSMSWVRQA PGKGLELVAQ 50
INSVGNSTYY PDTVKGRFTI SRDNAKNTLY LQMNSLRAED TAVYYCASGD 100
YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT 150
VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT QTYICNVNHK 200
PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR 350
DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK 442

DVVMTQSPLS LPVTLGQPAS ISCRSSQSLI YSDGNAYLHW FLQKPGQSPR 50
LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQSTHVP 100
Intra-H 22-96 139-195 256-316 362-420
22''-96'' 139''-195'' 256''-316'' 362''-420''
Intra-L 23'-93' 139'-199'
23'''-93''' 139'''-199'''
Inter-H-L 215-219' 215''-219'''
Inter-H-H 221-221'' 224-224''

H VH CDR2-IMGT N63:
56, 56''
H CH2 N84.4:
292, 292''
333

p. 264 & dalotuzumabum #

265
dalotuzumab replace the description and the structure by the following ones
dalotuzumab remplacer la description et la structure par les suivantes
dalotuzumab sustitúyase la descripción y la estructura por las siguientes
immunoglobulin G1-kappa, anti-[Homo sapiens IGF1R (insulin-like growth factor 1

receptor, IGF1-R, IGF-1R, CD221], humanized monoclonal antibody;
gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV4-61*08
(86.90%) -(IGHD)-IGHJ4*01) [9.7.10] (1-117) -Homo sapiens IGHG1*03 (118-
447)], (220-219')-disulfide with kappa light chain (1’-219’) [humanized V-KAPPA
(Homo sapiens IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo
sapiens IGKC*01 (113'-219')]; (226-226":229-229")-bisdisulfide dimer
immunoglobuline G1-kappa, anti-[Homo sapiens IGF1R (récepteur du facteur

de croissance 1 analogue à l’insuline (IGF1-R, IGF-1R, CD221)], anticorps
monoclonal humanisé;
chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens IGHV4-61*08
447)], (220-219')-disulfure avec la chaîne légère kappa (1’-219’) [V-KAPPA
humanisé (Homo sapiens IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112')
-Homo sapiens IGKC*01 (113'-219')]; dimère (226-226":229-229")-bisdisulfure
inmunoglobulina G1-kappa, anti-[Homo sapiens IGF1R (receptor del factor de

crecimiento similar a la insulina 1 (IGF1-R, IGF-1R, CD221)], anticuerpo
monoclonal humanizado;
cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens IGHV4-61*08
447)], (220-219')-disulfuro con la cadena ligera kappa (1’-219’) [V-KAPPA
humanizado (Homo sapiens IGKV2-29*03 (84.00%) -IGKJ1*01) [11.3.9] (1'-112') -
Homo sapiens IGKC*01 (113'-219')]; dímero (226-226":229-229")-bisdisulfuro

QVQLQESGPG LVKPSETLSL TCTVSGYSIT GGYLWNWIRQ PPGKGLEWIG 50
YISYDGTNNY KPSLKDRVTI SRDTSKNQFS LKLSSVTAAD TAVYYCARYG 100
RVFFDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250

DIVMTQSPLS LPVTPGEPAS ISCRSSQSIV HSNGNTYLQW YLQKPGQSPQ 50
LLIYKVSNRL YGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP 100
Intra-H 22-96 144-200 261-321 367-425
22''-96'' 144''-200'' 261''-321'' 367''-425''
Intra-L 23'-93' 139'-199'
23'''-93''' 139'''-199'''
Inter-H-L 220-219' 220''-219'''
Inter-H-H 226-226'' 229-229''

H CH2 N84.4
297, 297''
334

p. 70 lipegfilgrastimum #
lipegfilgrastim replace the description and the structure by the following ones
lipegfilgrastim remplacer la description et la structure par les suivantes
lipegfilgrastim sustitúyase la descripción y la estructura por las siguientes
pegylated granulocyte colony stimulating factor (human short isoform);

3.137
O -[{3,5-dideoxy-5-[(N-{[ω-methoxypoly(oxyethylene)]carbonyl}glycyl)amino]-
D-glycero-α-D-galacto-non-2-ulopyranosylonic acid}-(2→6)-2-(acetylamino)-2-deoxy-
α-D-galactopyranosyl]-des-(37-39)-[1-methionine]human granulocyte
colony-stimulating factor (G-CSF, pluripoietin)
facteur de stimulation de colonie de granulocytes (isoforme court humain) pégylé;

3.137
O -[{acide 3,5-didéoxy-5-[(N-{[ω-méthoxypoly(oxyéthylène)]carbonyl}glycyl)amino]-
D-glycéro-α-D-galacto-non-2-ulopyranosylonique}-(2→6)-2-(acétylamino)-2-déoxy-
α-D-galactopyranosyl]-dès-(37-39)-[1-méthionine]facteur humain de stimulation de
colonie de granulocytes (G-CSF, pluripoïétine)
factor de estimulacin de colonías de granulocitos (isoformo corto humano) pegilado;

3.137
O -[{acído 3,5-didesoxi-5-[(N-{[ω-metoxipoli(oxietileni)]carbonil}glicil)amino]-
D-glicero-α-D-galacto-non-2-ulopiranosilonico}-(2→6)-2-(acetilamino)-2-desoxi-
α-D-galactopiranosil]-dès-(37-39)-[1-metionina]factor humano de estimulación de
colonías de granulocitos (G-CSF, pluripoyetina)
MTPLGPASSL PQSFLLKCLE QVRKIQGDGA ALQEKL---C ATYKLCHPEE 50

LVLLGHSLGI PWAPLSSCPS QALQLAGCLS QLHSGLFLYQ GLLQALEGIS 100
PELGPTLDTL QLDVADFATT IWQQMEELGM APALQPTQGA MPAFASAFQR 150
RAGGVLVASH LQSFLEVSYR VLRHLAQP 178
40-46 68-78
Modified residues / Résidu modifié / Residuo modificado

HO OH
CO2H
T O
HO H O
137
PEG-Gly-Neu-GalNac-Thr O CH3
HN HO O H
H
H3C O N OH
O O H2 N CO2H
n HO NH
O
O
CH3
335
# Electronic structure available on Mednet: http://mednet.who.int/

# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/
Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.
336

DCI para Sustancias Farmacéuticas

Transféré par

Informations du document

Titre original

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

DCI para Sustancias Farmacéuticas

Transféré par

Droits d'auteur :

Formats disponibles

WHO Drug Information, Vol. 26, No.

3, 2012 Recommended INN: List 68

International Nonproprietary Names for

Dénominations communes internationales

Denominaciones Comunes Internacionales

Latin, English, French, Spanish:

DCI Recommandée Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

acide désoxycholique acide 3α,12α-dihydroxy-5β-cholan-24-oïque

ácido desoxicólico ácido 3α,12α-dihidroxi-5β-colan-24-oico

acide tiazotique acide [(5-méthyl-1H-1,2,4-triazol-3-yl)sulfanyl]acétique

ácido tiazótico ácido [(5-metil-1H-1,2,4-triazol-3-il)sulfanil]acético

bamosiran petit ARN interférant (siRNA) inhibiteur de la production du récepteur

bamosirán ARN interferente pequeño (siRNA) inhibidor de la producción del

caplacizumab immunoglobuline fragment VH-linker-VH, anti-[Homo sapiens VWF

caplacizumab inmunoglobulina fragmento VH-conector-VH, anti-[VWF (factor de

EVQLVESGGG LVQPGGSLRL SCAASGRTFS YNPMGWFRQA PGKGRELVAA 50

faldaprévir acide (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-méthoxy-

faldaprevir ácido (1R,2S)-1-{[(2S,4R)-4-[{8-bromo-7-methoxy-

flanvotumab immunoglobuline G1-kappa, anti-[Homo sapiens TYRP1 (protéine 1

flanvotumab inmunoglobulina G1-kappa, anti-[TYRP1 de Homo sapiens (proteina

Heavy chain / Chaîne lourde / Cadena pesada

Light chain / Chaîne légère / Cadena ligera

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

follitropine gamma hétérodimère constitué de la chaîne alpha des hormones

folitropina gamma heterodímero formado por la cadena alfa de las hormonas

Alpha subunit / Sous-unité alpha / Subunidad alfa

Beta subunit / Sous-unité bêta / Subunidad beta

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

élaïdate de gemcitabine 5'-(9E)-octadéc-9-énoate de 2'-déoxy-2',2'-difluorocytidine

elaidato de gemcitabina 5'-(9E)-octadec-9-enoato de 2'-desoxi-2',2'-difluorocitidina

phénylbutyrate de glycérol tris(4-phénylbutanoate) de propane-1,2,3-triyle

fenilbutirato de glicerol tris(4-fenilbutanoato) de propano-1,2,3-triilo

idursulfase bêta iduronate 2-sulfatase (α-L-iduronate sulfate sulfatase), proenzyme

idursulfasa beta iduronato 2-sulfatasa (α-L-iduronato sulfato sulfatasa), proenzima

SETQANSTTD ALNVLLIIVD DLRPSLGCYG DKLVRSPNID QLASHSLLFQ 50

Modified residue / Résidu modifié / Residuo modificado

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

inclacumab immunoglobuline G4-kappa, anti-[Homo sapiens SELP (sélectine P,

inclacumab inmunoglobulina G4-kappa, anti-[SELP de Homo sapiens (selectina

Heavy chain / Chaîne lourde / Cadena pesada

Light chain / Chaîne légère / Cadena ligera

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

patiromère calcique polymère réticulé de 2-fluoroprop-2-énoate de calcium avec du

patirómero cálcico polímero reticulado de 2-fluoroprop-2-enoato de calcio con

[[(C3H2FO2)2 Ca]9 [C8H14] [C10H10]]n

H2C CO2 CH2

patritumab immunoglobuline G1-kappa, anti-[Homo sapiens ERBB3 (récepteur

patritumab inmunoglobulina G1-kappa, anti-[Homo sapiens ERBB3 (receptor de

Heavy chain / Chaîne lourde / Cadena pesada

Light chain / Chaîne légère / Cadena ligera

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

pradigastat acide {trans-4-[4-(5-{[6-(trifluorométhyl)pyridin-3-yl]amino}pyridin-

pradigastat ácido {(1r,4r)-4-[4-(5-{[6-(trifluorometil)piridin-3-il]amino}piridin-2-il)

quilizumab immunoglobuline G1-kappa, anti-[Homo sapiens IGHE région de

quilizumab inmunoglobulina G1-kappa, anti-[Homo sapiens IGHE región de

Heavy chain / Chaîne lourde / Cadena pesada

Light chain / Chaîne légère / Cadena ligera

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

R(1-3) = R(5-11) = R(13-16) = R(18) = R(19) = -N(CH3)2

R(4) = R(12) = R(17) = HN N

romosozumab immunoglobuline G2-kappa, anti-[Homo sapiens SOST

romosozumab inmunoglobulina G2-kappa, anti-[SOST (esclerostina) de Homo